Translational value of mouse models in oncology drug development

Nature Medicine

Volumn 21, Issue 5, 2015, Pages 431-439

  Gould, Stephen E ^a   Junttila, Melissa R ^a   De Sauvage, Frederic J ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT;

ANIMAL MODEL; BIOLOGICAL ACTIVITY; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER MODEL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; METASTASIS INHIBITION; MOUSE; MOUSE MODEL; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SELECTION BIAS; STATISTICAL SIGNIFICANCE; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG DESIGN; DRUG INDUSTRY; GENETIC ENGINEERING; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASMS; PREDICTIVE VALUE; PROCEDURES; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG INDUSTRY; GENETIC ENGINEERING; HUMANS; IMMUNE SYSTEM; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84929172879     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3853     Document Type: Review

References (87)

1. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51 (2014).
2. Rangarajan, A. & Weinberg, R.A. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 3, 952-959 (2003).
3. Doudna, J.A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).
4. Fellmann, C. & Lowe, S.W. Stable RNA interference rules for silencing. Nat. Cell Biol. 16, 10-18 (2013).
5. Xue, W. et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380-384 (2014).
6. Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551-553 (2014).
7. Sánchez-Rivera, F.J. et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 428-431 (2014).
8. Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discovery 4, 998-1013 (2014).
9. Pantelouris, E.M. Absence of thymus in a mouse mutant. Nature 217, 370-371 (1968).
10. Rygaard, J. & Povlsen, C.O. Heterotransplantation of a human malignant tumour to 'Nude' mice. Acta Pathol. Microbiol. Scand. 77, 758-760 (1969).
11. Neve, R.M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
12. Domcke, S., Sinha, R., Levine, D.A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).
13. Klein, C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302-312 (2009).
14. Junttila, M.R. & de Sauvage, F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354 (2013).
15. Lodhia, K.A., Hadley, A., Haluska, P. & Scott, C.L. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim. Biophys. Acta 1855, 223-234 (2015).
16. Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311-1316 (2011).
17. DeRose, Y.S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514-1520 (2011).
18. Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116-1130 (2013).
19. Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422-426 (2014).
20. Das Thakur, M. & Stuart, D.D. Molecular Pathways: Response and resistance to BRAF and MEK inhibitors in BRAFV600E tumors. Clin. Cancer Res. 20, 1074-1080 (2013).
21. Julien, S. et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18, 5314-5328 (2012).
22. Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).
23. Hegde, G.V. et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci. Transl. Med. 5, 171ra18 (2013).
24. Martin, E.S. et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin. Cancer Res. 19, 2929-2940 (2013).
25. Westcott, P.M.K. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489-492 (2014).
26. Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014).
27. Gubin, M.M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
28. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
29. Walrath, J.C., Hawes, J.J., Van Dyke, T. & Reilly, K.M. Chapter 4: Genetically engineered mouse models in cancer research. In Advances in Cancer Research (Elsevier, 2010).
30. Mestas, J. & Hughes, C.C.W. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004).
31. Platzer, B., Stout, M. & Fiebiger, E. Antigen cross-presentation of immune complexes. Front Immunol 5, 140 (2014).
32. Hsieh, C.S., Macatonia, S.E., O'Garra, A. & Murphy, K.M. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181, 713-721 (1995).
33. Ito, R., Takahashi, T., Katano, I. & Ito, M. Current advances in humanized mouse models. Cell. Mol. Immunol. 9, 208-214 (2012).
34. Shultz, L.D., Brehm, M.A., Garcia-Martinez, J.V. & Greiner, D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12, 786-798 (2012).
35. Vatakis, D.N. et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 108, E1408-E1416 (2011).
36. Singh, M., Murriel, C.L. & Johnson, L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 72, 2695-2700 (2012).
37. Feldser, D.M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010).
38. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
39. Martins, C.P., Brown-Swigart, L. & Evan, G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006).
40. Junttila, M.R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010).
41. Zhou, Y. et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat. Biotechnol. 28, 71-78 (2010).
42. Huijbers, I.J. et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol. Med. 6, 212-225 (2014).
43. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
44. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
45. Forbes, S.A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2014).
46. Klijn, C. et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33, 306-312 (2015).
47. Wilson, T.R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
48. Utama, F.E. et al. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 150, 1782-1790 (2009).
49. Singh, M. et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585-593 (2010).
50. Ott, P.A., Hodi, F.S. & Robert, C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 19, 5300-5309 (2013).
51. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
52. Grosso, J.F. & Jure-Kunkel, M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5 (2013).
53. Herbst, R.S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
54. Junttila, T.T. et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 74, 5561-5571 (2014).
55. Saxena, M. & Christofori, G. Rebuilding cancer metastasis in the mouse. Mol. Oncol. 7, 283-296 (2013).
56. Francia, G., Cruz-Munoz, W., Man, S., Xu, P. & Kerbel, R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 11, 135-141 (2011).
57. Bos, P.D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009 (2009).
58. Minn, A.J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
59. Enquist, I.B. et al. Lymph node-independent liver metastasis in a model of metastatic colorectal cancer. Nat. Commun. 5, 3530 (2014).
60. Eisenhauer, E.A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
61. Johnson, J.I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
62. Voskoglou-Nomikos, T., Pater, J.L. & Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, 4227-4239 (2003).
63. Wong, H. et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin. Cancer Res. 18, 3846-3855 (2012).
64. Yauch, R. et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455, 406-410 (2008).
65. Gajjar, A. et al. Phase-I study of vismodegib in children with recurrent or refractory medulloblastoma: a Pediatric Brain Tumor Consortium (PBTC) study. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-13-1425 (27 September 2013).
66. Rudin, C. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178 (2009).
67. Wong, H. et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clin. Cancer Res. 17, 4682-4692 (2011).
68. Romer, J.T. et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6, 229-240 (2004).
69. Berlin, J.D. et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated Metastatic colorectal cancer. Clin. Cancer Res. 19, 258-267 (2012).
70. Wong, H. et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin. Cancer Res. 18, 3090-3099 (2012).
71. Wong, H. et al. Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J. Pharmacol. Exp. Ther. 329, 360-367 (2009).
72. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-1577 (2010).
73. Perrin, S. Preclinical research: Make mouse studies work. Nature 507, 423-425 (2014).
74. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
75. Bedard, P.L., Hansen, A.R., Ratain, M.J. & Siu, L.L. Tumour heterogeneity in the clinic. Nature 501, 355-364 (2013).
76. Marusyk, A. et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514, 54-58 (2014).
77. Couzin-Frankel, J. Hope in a mouse. Science 346, 28-29 (2014).
78. McFadden, D.G. et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298-1311 (2014).
79. Gersbach, C.A. Genome engineering: the next genomic revolution. Nat. Methods 11, 1009-1011 (2014).
80. Platt, R.J. et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440-455 (2014).
81. Chen, S. et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246-1260 (2015).
82. Lancaster, M.A. & Knoblich, J.A. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345, 1247125 (2014).
83. Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256-262 (2015).
84. Li, X. et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20, 769-777 (2014).
85. Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176-187 (2014).
86. Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141, 1762-1772 (2011).
87. Boj, S.F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324-338 (2015).